Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate
Authors:
- John R. JefferyJJJohn R. Jeffery
- William D. LeslieWLWilliam D. Leslie
- Martin E. KarpinskiMKMartin E. Karpinski
- Peter W. NickersonPNPeter W. Nickerson
- David N. RushDRDavid N. Rush
- 27 November 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (10) , 1498-1502
Abstract
Reduced bone mineral density (BMD) is common in long-term renal transplant recipients and results in a high incidence of fractures. The optimal therapy for these patients is not known. Baseline BMD determinations were obtained in 211 long-term adult renal transplant recipients. One hundred and seventeen patients with a reduced BMD (T score < or = -1) were randomly assigned to treatment with alendronate and calcium (n=60) versus calcitriol and calcium (n=57). Of these, 46 and 51 patients, respectively, completed 1 year of treatment. Forty-nine patients who were not eligible or did not consent to the trial were followed prospectively. Reduced baseline BMD (T score < or = -1) was present in 159 (78.7%) of patients at the lumbar spine or femur. There was no significant loss of BMD in the prospectively followed patients during 2.7 years. The average lumbar BMD increased from 0.984+/-0.149 to 1.025+/-0.143 g/cm2 (P<0.001) with alendronate and from 1.014+/-0.15 to 1.034+/-0.146 g/cm2 (P=0.002) with calcitriol. BMD at the femur increased from 0.809+/-0.092 to 0.836+/-0.107 g/cm2 (P<0.001) with alendronate and from 0.830+/-0.144 to 0.857+/-0.125 g/cm2 (P=0.023) with calcitriol. One year of treatment with alendronate or calcitriol, both with calcium supplementation, resulted in significant increases in BMD at the lumbar spine and femur, with a trend toward alendronate being more effective at the spine (P=0.082). Further studies are needed to determine whether BMDs continue to increase after 1 year and whether there is any additional benefit to combining vitamin D and alendronate. Larger studies are needed to determine whether treatment decreases fracture rates.Keywords
This publication has 29 references indexed in Scilit:
- Bone remodeling after renal transplantationKidney International, 2003
- Bone disease after renal transplantationTransplantation, 2003
- Bone mineral density changes within six months of renal transplantationTransplantation, 2003
- Development of lumbar bone mineral density in the late course after kidney transplantationAmerican Journal of Kidney Diseases, 2002
- Bone mineral density and fracture prevalence in long-term kidney graft recipientsTransplantation, 2002
- Risk factors for fractures in kidney transplantationTransplantation, 2002
- INCREASED FRACTURE RATE IN DIABETES MELLITUS AND FEMALES AFTER RENAL TRANSPLANTATION1Transplantation, 1999
- Evolution of bone mineral density after renal transplantation: related factorsNephrology Dialysis Transplantation, 1995
- Loss of Regional Bone Mineral Density in the First 12 Months following Renal TransplantationNephron, 1994
- Rapid Loss of Vertebral Mineral Density after Renal TransplantationNew England Journal of Medicine, 1991